Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gastroenteritis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Pipeline Review, H2 2016, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape. Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Gastroenteritis. Gastroenteritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Gastroenteritis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Gastroenteritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Gastroenteritis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Gastroenteritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Gastroenteritis (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Gastroenteritis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Gastroenteritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Gastroenteritis Overview 6 Therapeutics Development 7 Pipeline Products for Gastroenteritis - Overview 7 Pipeline Products for Gastroenteritis - Comparative Analysis 8 Gastroenteritis - Therapeutics under Development by Companies 9 Gastroenteritis - Therapeutics under Investigation by Universities/Institutes 10 Gastroenteritis - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Gastroenteritis - Products under Development by Companies 14 Gastroenteritis - Products under Investigation by Universities/Institutes 15 Gastroenteritis - Companies Involved in Therapeutics Development 16 Nanotherapeutics, Inc. 16 RedHill Biopharma Ltd. 17 Takeda Pharmaceutical Company Limited 18 UMN Pharma Inc. 19 Gastroenteritis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 Antibodies for Gastroenteritis - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 norovirus (bivalent) virus like particle vaccine - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 ondansetron hydrochloride CR - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 TAK-214 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 UMN-2002 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 UMN-2003 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Gastroenteritis - Product Development Milestones 39 Featured News & Press Releases 39 Jun 20, 2016: Takeda Initiates Worlds First Norovirus Vaccine Field Trial 39 Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102 39 Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D 40 Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 41 Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 42 Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 43 Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis 44 Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness 45 Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting 46 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Number of Products under Development for Gastroenteritis, H2 2016 7 Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Gastroenteritis - Pipeline by Nanotherapeutics, Inc., H2 2016 16 Gastroenteritis - Pipeline by RedHill Biopharma Ltd., H2 2016 17 Gastroenteritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 18 Gastroenteritis - Pipeline by UMN Pharma Inc., H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.